TScan Therapeutics, Inc. (TCRX) Stock Forecast
TCRX analyst forecast
as of October 18, 2026- Analyst consensus
- Hold 3.40 / 5 from 5 analysts
- Price target
- $1.00 average of analyst targets
- Upside to target
- +332.9% from the latest close
- Next earnings
- November 11, 2026 EPS estimate $-0.18
- 52-week range
- $0.21 – $2.52
TCRX analyst ratings
5 analystsNumber of analysts at each rating.
TCRX price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
TCRX earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.18 | −$0.23 | −$0.08 | −$0.28 | +34.8% | 4 |
| Current fiscal year (2026) | −$0.78 | −$0.89 | −$0.62 | −$1.00 | +22.2% | 4 |
| Next fiscal year (2027) | −$0.57 | −$1.03 | −$0.27 | −$0.78 | +26.4% | 4 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
TCRX revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $471,500 | $0 | $1.3M | −81.2% | 4 |
| Current fiscal year (2026) | $2.9M | $2.0M | $5.0M | −71.7% | 4 |
| Next fiscal year (2027) | $1.2M | $0 | $5.0M | −57.2% | 4 |
TCRX EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
TCRX revenue: reported and forecast
TCRX EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.21 | −$0.21 | −$0.22 | −$0.18 | −$0.18 | −15.1% | 2 up · 2 down |
| Current fiscal year (2026) | −$0.84 | −$0.84 | −$0.87 | −$0.78 | −$0.78 | −7.7% | 2 up · 1 down |
| Next fiscal year (2027) | −$0.89 | −$0.89 | −$0.94 | −$0.57 | −$0.57 | −35.5% | 4 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
TCRX earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; TCRX beat in 9 of 12.
What analysts expect from TCRX
5 analysts cover TScan Therapeutics; their consensus rating is hold (3.40 on a 1–5 scale, where 5 is a strong buy). The average price target is $1.00, 332.9% above the latest close of $0.23. Analysts expect earnings of −$0.78 per share for 2026, +22.2% from a year earlier. For 2027 the average estimate is −$0.57 per share on revenue of $1.2 million. TScan Therapeutics beat the EPS estimate in 9 of the last 12 quarters.
Related: TCRX income statement, TCRX key metrics, TCRX chart. See the TCRX stock overview for the latest quote and news.
TCRX forecast FAQ
What is TScan Therapeutics's price target?
The average analyst price target for TScan Therapeutics is $1.00, 332.9% above the latest close of $0.23.
Is TScan Therapeutics a buy, hold or sell?
Of 5 analysts covering TScan Therapeutics, 1 rate it a strong buy, 0 a buy, 4 a hold, 0 a sell and 0 a strong sell, a consensus of hold. Ratings are opinions, not a recommendation from Quotelinks.
What is TScan Therapeutics's EPS forecast?
Analysts forecast −$0.78 per share for 2026 (range −$0.89 to −$0.62); for 2027 the estimate is −$0.57.
What is TScan Therapeutics's revenue forecast?
The average revenue estimate for 2026 is $2.9 million, growth of −71.7%; for 2027 it is $1.2 million.
When does TScan Therapeutics report earnings?
TScan Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 11, 2026; the EPS estimate is $-0.18.
Does TScan Therapeutics usually beat earnings estimates?
TScan Therapeutics reported EPS at or above the analyst estimate in 9 of the last 12 quarters.